ATE494905T1 - Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom - Google Patents

Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom

Info

Publication number
ATE494905T1
ATE494905T1 AT08013828T AT08013828T ATE494905T1 AT E494905 T1 ATE494905 T1 AT E494905T1 AT 08013828 T AT08013828 T AT 08013828T AT 08013828 T AT08013828 T AT 08013828T AT E494905 T1 ATE494905 T1 AT E494905T1
Authority
AT
Austria
Prior art keywords
product
cancer
suppressor gene
tumor suppressor
vaccine containing
Prior art date
Application number
AT08013828T
Other languages
English (en)
Inventor
Tadanori Mayumi
Haruo Sugiyama
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadanori Mayumi
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Tadanori Mayumi, Haruo Sugiyama filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE494905T1 publication Critical patent/ATE494905T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08013828T 2001-06-29 2002-06-28 Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom ATE494905T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001199449 2001-06-29

Publications (1)

Publication Number Publication Date
ATE494905T1 true ATE494905T1 (de) 2011-01-15

Family

ID=19036745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08013828T ATE494905T1 (de) 2001-06-29 2002-06-28 Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom

Country Status (8)

Country Link
US (2) US20060165708A1 (de)
EP (2) EP1410804A4 (de)
JP (2) JP4229832B2 (de)
CN (1) CN1320923C (de)
AT (1) ATE494905T1 (de)
CA (1) CA2451846A1 (de)
DE (1) DE60238958D1 (de)
WO (1) WO2003002142A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
ATE470435T1 (de) * 2003-11-03 2010-06-15 Yissum Res Dev Co Verfahren zur auswahl von kationischen oder anionischen liposomen zur behandlung einer schleimhautmembran und diese enthaltendes set
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
EP1657250A1 (de) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A*01 bindendes T-Zell-Epitop von WT1
EP1951281B1 (de) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla klasse ii-bindungspeptide und diese umfassende zusammensetzungen und verfahren
JP5002749B2 (ja) * 2006-03-22 2012-08-15 富士フイルム株式会社 癌抑制剤
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
JP2008031063A (ja) * 2006-07-27 2008-02-14 Fujifilm Corp 癌抑制剤
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
WO2008105174A1 (ja) * 2007-02-28 2008-09-04 National University Corporation Hokkaido University 細胞性免疫誘導用リポソーム
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
EP2276495B1 (de) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulierung einer immunantwort durch enantiomere von kationischen lipiden
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
JP6082901B2 (ja) * 2011-01-31 2017-02-22 オリンパス株式会社 ワクチン・アジュバント
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US8562681B2 (en) 2012-01-31 2013-10-22 Styker Spine Laminoplasty implant, method and instrumentation
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
RS61173B1 (sr) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
DE102015201207B4 (de) 2014-06-24 2019-02-21 Sms Group Gmbh Viersattelpressenwerkzeug und Schmiedepresse sowie Verfahren zum Schmieden eines Werkstücks
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
US20250281465A1 (en) * 2022-04-27 2025-09-11 Dennis A. Carson Molecules that enhance extracellular vesicle release

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US104627A (en) 1870-06-21 Improvement in churn-power
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Also Published As

Publication number Publication date
US20090098197A1 (en) 2009-04-16
JP4229832B2 (ja) 2009-02-25
CA2451846A1 (en) 2003-01-09
EP1410804A4 (de) 2007-10-24
WO2003002142A8 (fr) 2003-12-11
CN1520311A (zh) 2004-08-11
CN1320923C (zh) 2007-06-13
EP2014300B1 (de) 2011-01-12
US20060165708A1 (en) 2006-07-27
HK1064589A1 (en) 2005-02-04
EP2014300A1 (de) 2009-01-14
DE60238958D1 (de) 2011-02-24
JPWO2003002142A1 (ja) 2004-10-14
JP2009079054A (ja) 2009-04-16
EP1410804A1 (de) 2004-04-21
WO2003002142A1 (fr) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE494905T1 (de) Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
DE60130799D1 (en) Synthese von 4-aminothalidomid enantiomeren
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20015073D0 (no) Vaksiner
ATE408601T1 (de) Fredericamycin-derivate
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
GEP20063895B (en) Platinum derivative pharmaceutical formulations
ATE297750T1 (de) Verwendung von hsp70 protein
MY209484A (en) Cpg amphiphiles and uses thereof
JO2178B1 (en) Treatment of emphysema using rar selective retinoid antagonists
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ATE317846T1 (de) Phosphoramidat-prodrugs
FR2746110B1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
DK0655926T3 (da) Ny sonde til tumordiagnose eller tumorterapi
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
DE69918961D1 (de) Verbesserte inhalationspräparate
PL368686A1 (en) Novel aminobenzoephenones
DE69514217D1 (de) Rekombinante plasmide enthaltende zusammensetzung und ihre verwendung als impstoff und arzneimittel
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties